OncoMatch/Clinical Trials/NCT05797168

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Is NCT05797168 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for ovarian cancer.

Phase 1/2RecruitingAstraZenecaNCT05797168Data as of May 2026

Treatment: AZD5335 · Saruparib (AZD5305) · Bevacizumab · Carboplatin · AZD9574 — This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Non-Small Cell Lung Carcinoma

Endometrial Cancer

Disease stage

Metastatic disease required

Participants with advanced solid tumors must have received prior adequate therapy in accordance with local practice for their tumor type and stage of disease

Performance status

ECOG 0–1(Restricted strenuous activity)

Lab requirements

Blood counts

Adequate organ and marrow function.

Kidney function

Adequate organ and marrow function.

Liver function

Adequate organ and marrow function.

Adequate organ and marrow function.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Research Site · Duarte, California
Research Site · Irvine, California
Research Site · La Jolla, California
Research Site · Aurora, Colorado
Research Site · Louisville, Kentucky

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify